Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer

AKMANSU M., Buyukberber S., Iren S., Demirci U., Kanyilmaz G., Coskun U., ...More

CASE REPORTS IN ONCOLOGY, vol.3, no.3, pp.480-488, 2010 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 3 Issue: 3
  • Publication Date: 2010
  • Doi Number: 10.1159/000323204
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus
  • Page Numbers: pp.480-488
  • Keywords: Cetuximab, Head and neck carcinoma, Irradiation, Radiotherapy, Recurrence
  • Gazi University Affiliated: Yes


We presented 9 recurrent head and neck carcinoma patients. Priorly all of them had received radiochemotherapy. We used cetuximab and irradiation concomitantly. Overall survival analysis of the patients was performed using the Kaplan-Meier method on SPSS version 15.0. Based on this calculation, mean follow-up duration is 12.8 months. Mean survival time is 19.8 months and annual mean survival rate is 59.3%.